IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$24.27 USD
-0.08 (-0.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $24.26 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, IDEAYA Biosciences, Inc. has a market cap of $2.13B, which represents its share price of $24.35 multiplied by its outstanding shares number of 87.58M. As a mid-cap company, IDYA's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
IDYA 24.27 -0.08(-0.33%)
Will IDYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IDYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDYA
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
IDYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
Other News for IDYA
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | IDYA ...
IDEAYA Biosciences (IDYA) Price Target Raised by JP Morgan | IDYA Stock News
JPMorgan Raises Price Target for Ideaya Biosciences (IDYA) Amid Growth Potential
JPMorgan ups Ideaya target, adds to Analyst Focus List
IDEAYA Biosciences Announces Key Presentation at ESMO 2025 for Phase 2 Trial in Uveal Melanoma ...